Comparison 1.
Artemether versus quinine
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Death | 16 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 1.1 Children | 12 | 1447 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.96 [0.76, 1.20] |
| 1.2 Adults | 4 | 716 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.59 [0.42, 0.83] |
| 2 Death: Time since admission to hospital | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 2.1 Death within 24 hours | 1 | 41 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.35 [0.02, 8.10] |
| 3 Coma resolution time (hours) | 6 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only | |
| 3.1 Children | 6 | 358 | Mean Difference (IV, Fixed, 95% CI) | ‐5.45 [‐7.90, ‐1.00] |
| 4 Neurological sequelae at discharge | 8 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 4.1 Children | 7 | 968 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.84 [0.66, 1.07] |
| 4.2 Adults | 1 | 560 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.92 [0.31, 27.86] |
| 5 Neurological sequelae at follow‐up | 2 | 566 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.82 [0.49, 1.38] |
| 5.1 Day 7 | 1 | 134 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.76 [0.27, 2.14] |
| 5.2 Day 28 | 1 | 432 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.84 [0.46, 1.53] |
| 6 Parasite clearance time | 8 | 446 | Mean Difference (IV, Fixed, 95% CI) | ‐8.82 [‐11.20, ‐6.45] |
| 6.1 Children | 7 | 420 | Mean Difference (IV, Fixed, 95% CI) | ‐9.03 [‐11.43, ‐6.63] |
| 6.2 Adults | 1 | 26 | Mean Difference (IV, Fixed, 95% CI) | 1.70 [‐15.56, 18.96] |
| 7 Proportion with parasite clearance | 1 | 74 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.88 [0.75, 1.04] |
| 7.1 At 72 hours | 1 | 37 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.88 [0.70, 1.11] |
| 7.2 At 7 days | 1 | 37 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.88 [0.70, 1.11] |
| 8 Fever clearance time (hours) | 9 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only | |
| 8.1 Children | 8 | 457 | Mean Difference (IV, Fixed, 95% CI) | ‐3.73 [‐6.55, ‐0.92] |
| 8.2 Adults | 1 | 26 | Mean Difference (IV, Fixed, 95% CI) | ‐29.70 [‐54.14, ‐5.26] |
| 9 Need for blood transfusion | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 9.1 Children | 1 | 103 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.27 [0.62, 2.59] |
| 9.2 Adults | 1 | 560 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.97 [0.73, 1.29] |
| 10 Episodes of hypoglycaemia | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 10.1 Children | 2 | 617 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.68 [0.44, 1.05] |
| 10.2 Adults | 1 | 560 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.44 [0.30, 0.64] |
| 11 Adverse events | 6 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 11.1 QT prolongation | 2 | 229 | Risk Ratio (M‐H, Fixed, 95% CI) | 3.10 [1.33, 7.19] |
| 11.2 Local skin reactions | 1 | 576 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.12 [0.03, 0.50] |
| 11.3 Abscess | 2 | 1136 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.20 [0.04, 0.90] |
| 11.4 Urticarial rash | 1 | 576 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.33 [0.01, 8.15] |
| 11.5 Supraventricular tachycardia | 1 | 54 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.23 [0.01, 4.59] |
| 11.6 Pruritus | 1 | 67 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.34 [0.01, 8.13] |
| 11.7 Urinary tract infection | 1 | 54 | Risk Ratio (M‐H, Fixed, 95% CI) | 3.46 [0.15, 81.36] |
| 11.8 Induration at injection site | 1 | 33 | Risk Ratio (M‐H, Fixed, 95% CI) | 15.44 [0.94, 253.49] |
| 11.9 Leg discomfort | 1 | 560 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.69 [0.22, 2.16] |
| 11.10 Chest infection | 1 | 560 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.11 [0.81, 1.53] |
| 11.11 GI bleeding | 1 | 560 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.79 [0.52, 1.20] |